Evidence map›Paper›PMID 37106368›Full record

ArticleTrials2023

Exploring implementation outcomes in the clinical trial context: a qualitative study of physician trial stakeholders.

Kristian D Stensland, Anne E Sales, Varsha K Vedapudi, Laura J Damschroder, Ted A Skolarus

Abstract read
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristian D StenslandDepartment of Urology, Dow Division of Health Services Research, University of Michigan, NCRC, Building 16, 100S-12, Ann Arbor, MI, 48109, USA. kstens@med.umich.edu.ORCID http://orcid.org/0000-0002-3765-3393
Anne E SalesUniversity of Missouri and Department of Family and Community Medicine, Sinclair School of Nursing, University of Missouri School of Medicine, Columbia, USA.
Varsha K VedapudiUniversity of Michigan, Ann Arbor, MI, USA.
Laura J DamschroderCenter for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Ted A SkolarusDepartment of Urology, Dow Division of Health Services Research, University of Michigan, NCRC, Building 16, 100S-12, Ann Arbor, MI, 48109, USA.

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Building capacity for clinical trial improvement through implementation scienceF32CA264874 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STENSLAND, KRISTIAN DONALD · 2021 to 2021
$84k
NCI NIH HHS F32 CA264874NCI NIH HHS R37 CA222885NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

introductionCancer clinical trials can be considered evidence-based interventions with substantial benefits, but suffer from poor implementation leading to low enrollment and frequent failure. Applying implementation science approaches such as outcomes frameworks to the trial context could aid in contextualizing and evaluating trial improvement strategies. However, the acceptability and appropriateness of these adapted outcomes to trial stakeholders are unclear. For these reasons, we interviewed cancer clinical trial physician stakeholders to explore how they perceive and address clinical trial implementation outcomes.

methodsWe purposively selected 15 cancer clinical trial physician stakeholders from our institution representing different specialties, trial roles, and trial sponsor types. We performed semi-structured interviews to explore a previous adaptation of Proctor's Implementation Outcomes Framework to the clinical trial context. Emergent themes from each outcome were developed.

resultsThe implementation outcomes were well understood and applicable (i.e., appropriate and acceptable) to clinical trial stakeholders. We describe cancer clinical trial physician stakeholder understanding of these outcomes and current application of these concepts. Trial feasibility and implementation cost were felt to be most critical to trial design and implementation. Trial penetration was most difficult to measure, primarily due to eligible patient identification. In general, we found that formal methods for trial improvement and trial implementation evaluation were poorly developed. Cancer clinical trial physician stakeholders referred to some design and implementation techniques used to improve trials, but these were infrequently formally evaluated or theory-based.

conclusionImplementation outcomes adapted to the trial context were acceptable and appropriate to cancer clinical trial physician stakeholders. Use of these outcomes could facilitate the evaluation and design of clinical trial improvement interventions. Additionally, these outcomes highlight potential areas for the development of new tools, for example informatics solutions, to improve the evaluation and implementation of clinical trials.

Indexed as

NeoplasmsPhysiciansHumansImplementation ScienceQualitative ResearchClinical trial improvementImplementation scienceOutcomes frameworksQualitative research

Identifiers

PMID37106368
PMCPMC10142148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.